Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.

Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid

Walgreens inked a partnership with VillageMD to provide primary care in Houston, the companies announced Wednesday.

Walgreens inks deal to offer primary care doctors next to some stores in Houston trial

The pharmacy chain has to walk a fine line, as the FDA is keeping close tabs on its moves.

Walgreen's New CBD Push Lets It Be Edgy Without Being Risky

CVS Health

There are fundamental problems for brick-and-mortar pharmacies that the companies may be unable to solve.

Deep Dive: Walgreens and CVS stocks look like tempting values, but investors may be swallowing a bitter pill

Costco

Revlon

Insider buying can be an encouraging signal for potential investors.

Insider Buys Of The Week: Costco, Walgreens, Revlon

AbbVie

A. O. Smith

Cardinal Health

Colgate-Palmolive

Federal Realty Investment Trust

General Dynamics

Hormel Foods

Coca-Cola

Dividend aristocrats and kings have proven themselves a great way to enjoy safe and growing dividends, even in recession, plus market-beating returns over time.

Bunker Dividend Growth Portfolio: Our Newest Dividend Aristocrat

Cronos Group

Charlotte's Web Holdings, Inc.

GW Pharmaceuticals

Global CBD sales could soar by 147% annually over the next four years.

9 Things You Must Know About CBD Before Investing in Pot Stocks

Walgreens Boots Alliance reported worse-than-expected numbers for Q2-2019 and took down annual guidance.

Can Walgreens Still Deliver The Growth Story?

Investors need to pay close attention to Walgreens Boots stock based on the movements in the options market lately.

Implied Volatility Surging for Walgreens Boots Stock Options

Walgreens Boots Alliance Inc. on Tuesday reported fiscal second-quarter results that fell short of expectations in what management described as  the "most difficult" quarter since late 2014.

Analysts React To The Walgreens Q2 Earnings Miss

Outgoing Food and Drug Administration Commissioner Scott Gottlieb told lawmakers Wednesday that he's uneasy about Walgreens' and CVS' recent decisions to start selling CBD products in their drugstores.

Outgoing FDA chief Gottlieb raises 'concern' over Walgreens, CVS selling CBD products

Walgreens Boots Alliance, Inc (WBA) CEO Stefano Pessina on Q2 2019 Results - Earnings Call Transcript

The pharmacy chain is stumbling after a difficult quarter. Here's what investors need to know.

Why Walgreens Boots Alliance Stock Plunged Today

Walgreens management has lost credibility with analysts, and that--for any company--is a situation in which owning its stock can be an expensive mistake.

Walgreens Shares Are Still Worth Shorting Even After Today's Huge Decline

Walgreens Boots Alliance Inc.'s stock  plummeted 12.3% in morning trade, putting them on track for a 5-year closing low, after the drugstore chain's disappointing earnings report and slashed profit-growth guidance.

Walgreens stock plunge drags down Dow, CVS and consumer staples ETF

Walgreens Boots Alliance Inc. released its fiscal second-quarter financial results before the markets opened on Tuesday.

How Walgreens Tripped Up in Q2

Walgreens delivered earnings and revenue surprises of -3.53% and -0.89%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance Lags Q2 Earnings and Revenue Estimates

Shares of Walgreens Boots Alliance Inc.  tumbled 6.4% in premarket trade Tuesday, after the drugstore chain reported fiscal second-quarter earnings that missed expectations.

Walgreens' stock tumbles after profit miss and slashed guidance, as challenges accelerated

Walgreens Boots Alliance missed fiscal second-quarter earnings estimates. The Dow Jones drug store giant also cut full-year EPS guidance.

Walgreens Earnings, Sales, Guidance Weak

Walgreens misses quarterly earnings estimates, lowers full-year forecast

Walgreens' shares slide as drugstore chain misses earnings estimates, lowers 2019 forecast

Archer-Daniels-Midland Company

Polaris

SEI Investments

To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years.

Dividend Growth Stocks

Walgreens Boots Alliance Inc. is scheduled to release its fiscal second-quarter financial results before the markets open on Tuesday.

What to Expect When Walgreens Reports Tuesday Morning

Walgreens' plan to sell CBD creams, patches and sprays follows a similar deal by rival CVS days ago. Marijuana stocks traded broadly lower.

The 2 Largest Drugstore Chains Are Now In The Pot Products Business

Shares of Walgreens Boots Alliance, Inc. (WBA) have fallen roughly 9% this year, which stands in contrast to the market's nearly 13% climb and its industry's 4.5% average gains.

Buy Walgreens (WBA) Stock Ahead of Q2 Earnings, Before CBD Push?

Walgreens Boots Alliance Inc. plans to start selling products containing cannabidiol.

News for Walgreens Stock (WBA)